ESC 365 - What makes FXI inhibition different from current approaches to thrombosis prevention?

Open Access

What makes FXI inhibition different from current approaches to thrombosis prevention?

Session: How could factor eleven (FXI) inhibitors help your patients? New frontiers in thrombosis prevention

Topic: Atrial Fibrillation (AF)

Speaker: Professor V. Caso (Perugia, IT)

Sponsored by Bayer AG

Event: ESC Congress 2022

Congress Presentation

Add to my library

About the speaker

Professor Valeria Caso

Hospital Santa Maria Della Misericordia, Perugia (Italy)

11 presentations

7 followers

3 more presentations in this session

Welcome and introduction.

Speaker: Doctor M. Patel (Durham, US)

Which patients will benefit most from FXI inhibition?

Speaker: Professor V. Kunadian (Newcastle-Upon-Tyne, GB)

Live Q&A.

Access the full session

How could factor eleven (FXI) inhibitors help your patients? New frontiers in thrombosis prevention

Speakers: Professor V. Caso, Doctor M. Patel, Professor V. Kunadian

About the event

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress

ESC 365 is supported by

bristol-myers-squibb

Explore sponsored resources

novartis

Explore sponsored resources